Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 272-277

  Chang, H ^a,b   Rha, S Y ^a,b   Jeung, H C ^a,b   Im, C K ^a,b   Ahn, J B ^a,b   Kwon, W S ^a   Yoo, N C ^a,b   Roh, J K ^a,b   Chung, H C ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

ABCB1 polymorphism; Breast neoplasms; Paclitaxel; Tumor response

Indexed keywords

ANTHRACYCLINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HOMOZYGOTE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 60549112572     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn624     Document Type: Article

References (30)

1. Fountzilas G, Athanassiades A, Giannakakis T et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996; 32A: 47-51.
2. Jung JY, Jeong HC, Yoon SS et al. A phase II study of Genexol®(paclitaxel) in metastatic breast cancer. Cancer Res Treat 2001; 33: 451-457.
3. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22: 7280-7295.
4. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: Review and meta-analysis. Semin Oncol 2005; 32(6 Suppl 7): S9-S15.
5. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006; 95: 2293-2308.
6. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310.
7. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
8. Tanabe M, Ieiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
9. Awada A, Biganzoli L, Cufer T et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. Eur J Cancer 2002; 38: 773-778.
10. Rivera E, Sutton L, Colwell B et al. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. J Clin Oncol 2002; 20: 987-993.
11. Ikubo S, Takigawa N, Ueoka H et al. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. Anticancer Res 1999; 19: 3985-3988.
12. Duan Z, Feller AJ, Penson RT et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5: 3445-3453.
13. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
14. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93: 293-301.
15. Guo B, Villeneuve DJ, Hembruff SL et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004; 85: 31-51.
16. Duan Z, Brakora KA, Seiden MV. MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene 2004; 340: 53-59.
17. Villeneuve DJ, Hembruff SL, Veitch Z et al. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 2006; 96: 17-39.
18. Kars MD, Iseri OD, Gündüz U et al. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006; 26: 4559-4568.
19. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S22-S26.
20. Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol 2005; 32: S16-S21.
21. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-7523.
22. Tsukamoto F, Shiba E, Taguchi T et al. Immunohistochemical detection of P-glycoprotein in breast cancer and its significance as a prognostic factor. Breast Cancer 1997; 4: 259-263.
23. Burger H, Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 2003; 9: 827-836.
24. Kafka A, Sauer G, Jaeger C et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117-1121.
25. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
26. Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962.
27. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001; 97: 3605-3611.
28. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25: 1-6.
29. Mantovani I, Cappellini A, Tazzari PL et al. Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol 2006; 207: 836-844.
30. Nordgard SH, Ritchie MD, Jensrud SD et al. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 2007; 17: 127-136.